Gene therapy with covalently closed-end AAV vector for spinal muscular atrophy

2025-06-14

PRE

Haolin Duan

Ciliu Zhang

Zhong-Liang Zhang

Xiaole Wang

Junping Zhang

Lifen Yang

Fang He

Leilei Mao

Li Yang

Pan Zou

Renzhi Han

Weiming Wang

Dao Pan

Fei Yin

Weidong Xiao *

Jing Peng *

DOI：10.1016/j.ymthe.2025.06.028

Original

Original request for help

Save

Abstract

En 中文

Covalently closed-end adeno-associated virus (cceAAV) vector is a new generation of self-complementary adeno-associated virus (scAAV) vector that does not utilize a mutant inverted terminal repeat (ITR) for vector production. Importantly, packaged genomes of these cceAAV vectors are markedly more intact than traditional scAAVs, which typically contain a large fraction of incomplete genomes, including many that lost their self-complementary configuration. Here, we report the first in-human experience with a cceAAV vector. High quality clinical grade cceAAV vector based on AAV serotype 9 (AAV9) was produced in 200 L of suspension 293 cells with a total yield of 4.3 × 1016 vector genomes (vg). Clinical trial in two spinal muscular atrophy (SMA) patients via intravenous injection at 12–24 months of age revealed no treatment-associated severe adverse events with a dose ranging from 6 × 1013 to 1.2 × 1014 vg/kg. Both patients showed rapid improvements in motor capabilities after gene therapy, as evidenced by substantial gains in motor function and electrophysiological parameters and capacity for independent mobility. Our strategy enabled us to perform gene therapy in older SMA patients who had received initial treatment with RNA-splicing modifying drug during infancy. These early data provide preliminary evidence for clinical use of cceAAV vectors, though further validation in larger cohorts is warranted.

Gene therapy with covalently closed-end AAV vector for spinal muscular atrophy

Abstract

Journal

Organization

Cited Papers

Citing Papers